Acting Executive Director & Chairman of the Board; President, DEKA Research & Development
Dean Kamen is an inventor, an entrepreneur, and a tireless advocate for science and technology. His roles as inventor and advocate are intertwined with his passion for technology and its practical uses.
As the Acting Director & Chairman of the Board of Directors for ARMI, Kamen will guide the institute, a first-of-its-kind innovation accelerator, as it makes practical the large-scale manufacturing of engineered tissues and tissue-related technologies, to benefit existing industries and grow new ones.
In 1982, he founded DEKA to focus on medical innovations aimed to improve lives around the world. Kamen has received many awards for his efforts. Notably, Kamen was awarded the National Medal of Technology in 2000. Presented by President Clinton, this award was in recognition for inventions that have advanced medical care worldwide, and for innovative and imaginative leadership in awakening America to the excitement of science and technology. Kamen was also awarded the Lemelson-MIT Prize in 2002, and was inducted into the National Inventors Hall of Fame in May 2005. He is a Fellow of the American Institute for Medical & Biological Engineering, and has been a member of the National Academy of Engineering since 1997.
In addition to DEKA, one of Kamen’s proudest accomplishments is founding FIRST® (For Inspiration and Recognition of Science and Technology), a non-profit organization dedicated to motivating the next generation to understand, use, and enjoy science and technology. Founded in 1989, FIRST serves nearly 500,000 young people, ages 6 to 18, in more than 85 countries around the globe. In 2016, Kamen extended the reach of robotics competitions globally with the founding of FIRST Global, an international competition where one team from every nation is invited to participate in an event that builds bridges between high school students with different backgrounds, languages, religions, and customs. The inaugural FIRST Global event took place in Washington D.C. in July of 2017.
MAUREEN K. TOOHEY
Acting Deputy Executive Director & Secretary of the Board; Founder, Toohey Law Group
Maureen K. Toohey is the Acting Deputy Executive Director for ARMI and serves as Secretary of the Board where she manages all facets of building an entirely new sector through an industry, government and academic collaboration accelerating the deployment of emerging large-scale manufacturing of engineered tissues and tissue-related technologies. Drawing from her past experiences as an entrepreneur, intellectual property expert, and new business development professional, Maureen brings a unique perspective to ARMI’s efforts to foster innovation, encourage collaboration, and drive economic growth.
Toohey is the founding member of the Toohey Law Group LLC where she counsels clients regarding the strategic protection and transfer of intellectual property rights, supervises the prosecution of intellectual property portfolios, and litigates intellectual property disputes. Prior to founding the Toohey Law Group in 2007, Maureen served as General Counsel for DEKA Research & Development Corporation. Maureen also practiced in the Silicon Valley Office of Weil, Gotshal & Manges LLP.
Toohey received a B.S. in Chemistry from the United States Naval Academy at Annapolis, MD. After serving on active duty in the United States Navy, she attended law school at the University of Virginia School of Law and received her J.D. in 1996.
Additionally, Maureen is active in the Federal Circuit Bar Association, AIPLA, and IP Law Section of the ABA, and serves as an advisor to FIRST (For Inspiration and Recognition of Science and Technology), a non-profit organization dedicated to inspiring young people to pursue a career in science and engineering.
RICHARD D. McFARLAND, Ph.D., M.D.
Chief Regulatory Officer
Richard McFarland, Ph.D., M.D. joined ARMI as its Chief Regulatory Officer on May 1, 2017. Dr. McFarland comes to ARMI from the Food and Drug Administration’s Center for Biologics Evaluation and Research (FDA/CBER) where his career spanning 16 years involved review over an extensive range of products and policy development in numerous areas both inside FDA, across the federal government, and internationally. He spent more than a decade as Associate Director of Policy for FDA/CBER’s Office of Tissues and Advanced Therapies and its predecessor office, the Office of Cellular, Tissue and Gene Therapies. In this position, he was heavily involved in policy development for tissue engineering, regenerative medicine, and alternatives to animal use in regulatory decision making. In addition to development of risk-based regulatory oversight paradigms within FDA, his interests included broader efforts to create an interlocking network of interagency efforts to foster growth of basic and translational science to support maturation of the overlapping fields of tissue engineering and regenerative medicine from primarily discovery science toward a stage of commercial development.
His position at ARMI will allow him to apply the knowledge and experiences gained over the last decade and half in the field to ARMI’s efforts to establish an industrial common, in the form of a Manufacturing Innovation Institute within the Manufacturing USA network, with the aims to coalesce the field and provide a route for nascent product concepts to reach the marketplace. Bringing these products to the market will benefit critical U.S. public health needs and will provide the economic drivers needed to create new highly-skilled jobs.
Dr. McFarland, Ph.D., M. D. received his B.S., Ph.D., and M.D. from the University of North Carolina at Chapel Hill, and completed his anatomic/clinical pathology residency and immunopathology fellowship training at UT Southwestern in Dallas. Immediately prior to joining the FDA, he was on the faculty of the Pathology Department of the University of Texas Southwestern in Dallas. In addition to FDA policy documents he has co-authored over 25 articles in peer-reviewed articles journals including Nature, the Proceedings of the National Academy of Science (PNAS), and Blood.
Chief Workforce Officer; Dean, University of New Hampshire, Manchester
Mike Decelle serves as the Chief Workforce Office for ARMI. In this role, he is responsible for the identification and implementation of strategies that develop the educated and trained workforce required for the long-term, sustainable growth of the advanced tissue bio fabrication industry. He works with a nationwide network of industry and educational partners that bring a diverse perspective to the needs of this emerging technology space.
Mike Decelle is the Dean of UNH Manchester, a multidisciplinary, research college of the University of New Hampshire and the convening site for ARMI’s education and workforce development partner network. He assumed leadership of the Manchester campus in February 2016 following a 35-year career in the technology sector as an engineer, corporate executive, and startup company CEO. Dean Decelle has deep experience in the commercialization of early-stage, advanced technologies, in both large company environments as well as in small startups.
Dean Decelle graduated from UNH with a Bachelor’s in Electrical Engineering, and was recruited on campus by Bell Laboratories and accepted into their graduate fellowship program, earning a Master’s in Electrical Engineering from Cornell. He later completed the Program for Management Development at Harvard University. Dean Decelle worked at Bell and, after its spinoff from AT&T, at Lucent Technologies for 17 years. Since then he has led as CEO to five venture-funded technology companies, three of which were university spinoffs. During his tenure at Sun Catalytix, an MIT-spinout, Dean Decelle established the company’s reputation as an emerging leader in energy storage technology and systems, and developed relationships with strategic partners that led to Lockheed Martin acquiring the company in 2014. Most recently, Dean Decelle was president and CEO of CrossFiber, a venture-funded startup company in San Diego which he led until its sale in 2016.
Dean Decelle is an experienced technologist and engineer. The startup companies he has led began as small ventures without well-formed market or product plans. These companies spanned a range of technical areas including optical and data networking, semiconductor design and manufacturing, image processing, grid-scale energy storage, and microelectromechanical systems (MEMS).
THOMAS BOLLENBACH, Ph.D.
Chief Technology Officer
Dr. Tom Bollenbach is the Chief Technology Officer for ARMI where he is building the mechanisms necessary to turn laboratory breakthroughs into manufactured products through the integration of innovative cell and tissue culture with recent advances in biofabrication, automation, robotics, and analytical technologies creating disruptive research and development tools and FDA-compliant volume manufacturing processes.
Prior to joining ARMI, Dr. Bollenbach was the Vice President for Research and Development at Harvard Apparatus Regenerative Technology (formerly HART, now Biostage) where he was responsible for the development and execution of IND-enabling preclinical and product development programs for implantable airway and esophageal constructs containing living cells.
Before HART, he was the Associate Director of Preclinical R&D at Organogenesis Inc., where he implemented and completed IND-enabling efficacy and preclinical pharmacology and toxicology programs for living, bioengineered skin grafts.
Dr. Bollenbach earned his Ph.D. in Biochemistry from the University of Notre Dame and his B.Sc. in Biochemistry from the University of Waterloo, Canada
Acting Chief Operating Officer
Jim Scott is the acting Chief Operating Officer of ARMI where he oversees all operational and administrative areas.
Since 2004, Jim has been responsible for business development at DEKA Research & Development Corporation. During this time, he assisted DEKA in the development of new products in partnership with industry-leading companies in such diverse fields as: regenerative medicine, medical devices, energy, and consumer products. Before joining DEKA, Jim worked for Northbridge, a boutique infrastructure financing firm in Washington D.C.
He holds a BA from Williams College and an MBA from the University of North Carolina at Chapel Hill.
Chief Membership Officer
Gray Chynoweth is the Chief Membership Officer for ARMI where he oversees day-to-day operations and membership development activities.
Prior to ARMI, Gray was an executive at multiple New Hampshire based technology companies. As the first non-founding executive team member at Dyn (acquired by Oracle), Gray helped scale the company less than 20 to more than 450 employees, raise more than $38,000,000 in venture capital funding, grow revenue 30x and establish global operations, with offices in the US, the UK and Australia.
He also serves or has served as a as a board member for many for-profit and not-for-profit corporations.
Gray holds degrees from Duke University: a J.D. from University School of Law; and an M.A. in Public Policy from the Sanford School of Public Policy at Duke University. He was also awarded a B.A. in Political Science from the University of California at Berkley, where he graduated magna cum laude.